# SELUTION SLR™ DEB

# DRUGELUTION DONE BETTER

SUCCESS PTA STUDY

The next step in the evolution of Leave Nothing Behind with Sustained Limus Release.

Consistent performance in complex patients show SELUTION SLR™ Drug-Eluting Balloon meets or exceeds effectiveness of Paclitaxel eluting technologies.

STUDY DESIGN

A multi-center, prospective, observational evaluation of real-world, real-practice PAD population at 12 months. Primary end-point of clinically driven TLR at 12 months.<sup>1</sup>

**723** 

41

**PATIENTS** 

SITES

Europe, Asia, and South America

74.2%

**CLAUDICANT** 

**25.8**%

CRITICAL LIMB-THREATENING ISCHEMIA (CLTI)

**12.8**см

**LESION LENGTH** 

16.3%

SEVERE CALCIFICATION

**42.1**%

СТО

37.9%

**DIABETES** 

**16.8**%


**RENAL FAILURE** 



STUDY RESULTS


# BEST-IN-CLASS FREEDOM FROM CD-TLR

# IN COMPLEX PATIENT GROUPS




#### **POSITIVE RESULTS THAT ARE COMPARABLE TO PACLITAXEL DCBS\***

#### 12 Months Freedom from CD-TLR



#### **MAINTAINED CLINICAL IMPROVEMENT**

Rutherford Classification Through 12 Months



SELUTION SLR™ DEB

### RESULTS WITHOUT COMPROMISE





To learn more, scan the QR Code



- 1. 12 Months SUCCESS PTA Study, Oral Presentation, Charing Cross 2025
- Zeller, et al. Circ Cardiovasc Interv. 2019
  Lichtenberg, et al. Journal of Cardio Surg 2018
- 4. Tepe, et al. Journ Endovasc Therapy 2020

#### For Healthcare Professionals Only.